[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bleeding":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,47,70,106,134,165,193,224,252,281,303,331,354,374,395,426,450,473,496,523,562,589,612,638,663],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100366007","phase-3-anticoagulation-for-new-onset-post-operative-atrial-fibrillation-after-cabg-100366007",false,"NCT04045665","Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","PACES","Inclusion Criteria:\n\n* Patients of age ≥18 years who undergo isolated CABG for coronary artery disease\n* POAF that persists for \\>60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery\n\nExclusion Criteria:\n\n* Clinical history of either permanent, persistent or paroxysmal atrial fibrillation\n* Any pre-existing clinical indication for long-term OAC\n* Any absolute contraindication to OAC\n* Planned use of post-operative dual antiplatelet therapy (DAPT)\n\n  a. This includes, but is not limited to, patients with recent PCI with drug-eluting or bare-metal stent.\n* Cardiogenic shock\n* Major perioperative complication\\* occurring between CABG and randomization\n\n  a. including, but not limited to, stroke, TIA, MI, major bleeding (BARC type 4 bleeding), severe sepsis, renal failure requiring dialysis, or need for reoperation due to bleeding (e.g. pericardial tamponade).\n* Concomitant left atrial appendage closure during CABG\n* Concomitant valve surgery during CABG or prior valve surgery (including aortic, mitral, tricuspid or pulmonary)\n* Concomitant mitral valve annuloplasty during CABG\n* Concomitant carotid artery endarterectomy during CABG\n* Concomitant aortic root replacement during CABG\n* Concomitant surgery for AF during CABG\n* Liver cirrhosis or Child-Pugh Class C chronic liver disease\n* Pharmacologic therapy with an investigational drug or device within 30-days prior to randomization or plan to enroll patient in an investigational drug or device trial during participation in this trial\n* Pregnancy at the time of randomization\n* Unable or unwilling to provide inform consent\n* Unable or unwilling to comply with the study treatment and follow-up\n* Existence of underlying disease that limits life expectancy to less than one year","ALL","18 Years",{"count":20,"type":21},3200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.\n\nAll patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey.",[27,28,29],"Atrial Fibrillation","Stroke","Bleeding",[31,32,33],"Anticoagulation","Antiplatelet Therapy","Post Operative Atrial Fibrillation","RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":38},"2019-12-13",{"date":42,"type":21},"2026-08-31",{"name":44,"class":45},"Icahn School of Medicine at Mount Sinai","OTHER",106,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100405162","phase-4-enhancement-of-the-haemostatic-effect-of-platelets-in-the-presence-of-high-normal-concentrations-of-von-willebrand-factor-100405162","NCT04555785","Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor","Will-Plate","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to intensive care unit\n* Patients needing platelet transfusion during or after surgery with or without prior treatment with single or dual antiplatelet agents (ASS, Prasugrel, Clopidogrel, Ticagrelor)\n* Consent by the patient or a family member in addition to the consent of an independent ICU physician\n\nExclusion Criteria:\n\n* Patients receiving Factor VIII concentrate before inclusion of the study (Haemate ®)\n* Women who are pregnant or breastfeeding\n* Participation in another study with an investigational drug within the 30 days preceding and during the present study\n* Overt Disseminated Intravascular Coagulation (DIC)\n* Heparin-induced Thrombocytopenia (HIT)\n* Thrombotic Thrombocytopenic Purpura (TTP) or Haemolytic uremic Syndrome (HUS)\n* Idiopathic thrombocytopenic purpura (ITP)\n* Sepsis\n* Patients with known inherited thrombocytopathies\n* Patients with known von Willebrand disease or Haemophilia A\n* Patients with known hemato-oncological diseases\n* Previous enrolment into the current study\n* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product.",{"count":55,"type":21},120,[57],"PHASE4","Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.",[29],"2026-06-10",{"date":62,"type":38},"2026-06-11",{"date":64,"type":38},"2022-04-01",{"date":66,"type":21},"2028-11",{"name":68,"class":45},"University Hospital, Basel, Switzerland",1,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100642101","phase-4-study-of-aspirin-removal-in-patients-supported-by-the-fully-magnetically-levitated-ch-vad-pump-100642101","NCT07644247","STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump","A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump (STAR Trial)","STAR","Inclusion Criteria:\n\n\\-\n\nStudy participants must meet all the following criteria:\n\n1. Age ≥18 years old;\n2. Implanted with the CH-VAD pump for advanced heart failure, and the CH-VAD pump is the first implanted left ventricular assist device;\n3. Able to understand the study purpose, voluntarily participate and sign the informed consent form, and willing to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n\\-\n\nStudy participants meet any of the following criteria will be excluded:\n\n1. Requirement for additional temporary or permanent mechanical circulatory support after LVAD implantation;\n2. Requirement for physician-mandated antiplatelet therapy after implantation due to medical history, surgical history, concomitant surgical procedures, or other conditions, including mandated presence or absence of antiplatelet agent;\n3. Occurrence of primary endpoint events prior to randomization (within 2-7 days after implantation);\n4. Inability to take oral medications post-implant through 7 days;\n5. Known allergy to aspirin;\n6. Participation in another clinical investigation that may affect study outcome;\n7. Presence of other comorbid conditions, social or psychological conditions, or other conditions, in the investigator's opinion, that may affect participation in the study or compliance with follow-up requirements.",{"count":79,"type":21},370,[57],"This multi-center, prospective, randomized, double-blinded, placebo-controlled study aims to investigate whether withdrawal of aspirin from the antithrombotic regimen in patients supported with the CH-VAD pump is non-inferior to the standard antithrombotic regimen of vitamin K antagonist combined with aspirin in terms of safety and efficacy.",[83,84,85,86,29,87,28,88,89,90,32,91],"LVAD (Left Ventricular Assist Device) Thrombosis","LVAD","LVAD (Left Ventricular Assist Device)","LVAD-related GI Bleed","Thrombosis","Hemocompatibility-related Adverse Event","Ventricular Assist Device","Aspirin","Antithrombotic Therapy",[93,84,28,29,87,94,90,95],"Left ventricular assist device","Hemocompatibility","Antiplatelet","NOT_YET_RECRUITING","2026-06-08",{"date":99,"type":38},"2026-06-12",{"date":35,"type":21},{"date":102,"type":21},"2029-12-31",{"name":104,"class":105},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":69},"100566649","phase-2-preoperative-tranexamic-acid-txa-to-prevent-bleeding-in-patients-undergoing-major-colorectal-surgery-100566649","NCT06657924","Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery","Inclusion Criteria:\n\n1. Adults 18 years or older\n2. Undergoing elective or non-elective inpatient abdominal and pelvic colorectal surgery\n\nExclusion Criteria:\n\n1. Creatinine clearance less than 30 mL\u002Fminute\n2. Long-term dialysis\n3. Known defective color vision (color blind)\n4. Pregnancy\n5. History of venous or arterial thromboembolism, or active thromboembolic disease\n6. Disseminated intravascular coagulation (DIC) - clinically suspected and\u002For confirmed by platelet count on CBC, fibrinogen, INR and PTT.","100 Years",{"count":114,"type":21},394,[116],"PHASE2","The goal of this prospective pragmatic randomized clinical trial is to determine if preoperative administration of tranexamic acid (TXA) reduces bleeding during and after major colorectal surgery. The primary questions are:\n\n* Does TXA reduce bleeding during and after surgery (change in hemoglobin from before surgery to lowest value after surgery within 30 days)\n* Does TXA reduce bleeding complications within 30 days of surgery (blood transfusion, return to the operating room or procedural intervention for bleeding, death due to bleeding)\n* Does TXA increase the risk of thromboembolic complications within 30 days of surgery (cerebrovascular accident, myocardial infarction, deep venous thrombosis, pulmonary embolism)\n\nResearchers will compare preoperative TXA to no TXA to answer the above questions.\n\nParticipants who receive TXA will receive 1 g TXA IV at the beginning and end of surgery in the operating room.",[29,119,120,121],"Colorectal Disorders","Thromboembolism","Tranexamic Acid",[121,123,29,124,120],"TXA","Colorectal Surgery","2026-05-27",{"date":127,"type":38},"2026-05-28",{"date":129,"type":38},"2025-02-11",{"date":131,"type":21},"2027-10-01",{"name":133,"class":45},"Kristen Ban",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":69},"100584513","timing-of-anticoagulant-administration-during-radial-access-percutaneous-coronary-intervention-the-hera-pci-study-heparin-early-for-radial-access-percutaneous-coronary-intervention-100584513","NCT06890312","Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)","HERA-PCI","Inclusion Criteria:\n\n* Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention\n* Subject affiliated to a social protection health insurance\n* Subject able to understand the objectives and risks of the research and to provide dated and signed consent\n* Subject who has been informed of the results of the preliminary medical examination\n\nExclusion Criteria:\n\n* Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)\n* Very high bleeding risk defined by recent bleeding (\\\u003C6 months) of type 3 of the BARC classification\n* Subject in an exclusion period (determined by a previous or ongoing study)\n* Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)\n* Subject under safeguard of justice\n* Subject under guardianship or curatorship\n* Pregnancy\n* Breastfeeding\n* Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).",{"count":142,"type":21},550,[144],"NA","While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.",[147,148,149,29,31],"Coronary Angiography","Percutaneous Coronary Intervention","Radial Artery Occlusion",[151,152,153,154,155],"Anticoagulant injection timing","Percutaneous coronary intervention","Coronary angiography","Radial artery occlusion prevention","Bleeding events","2026-05-20",{"date":158,"type":38},"2026-05-26",{"date":160,"type":38},"2025-06-05",{"date":162,"type":21},"2028-01",{"name":164,"class":45},"University Hospital, Strasbourg, France",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":192},"100542051","phase-3-bleeding-reduction-in-acute-and-chronic-kidney-patients-having-surgery-brackets-pilot-trial-100542051","NCT06337838","Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial","Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial","BRACKETS","Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:\n\n1. One of either:\n\n   1.1. eGFR \\\u003C25 ml\u002Fmin\u002F1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;\n2. Planned noncardiac surgery (elective, urgent, or emergency surgery);\n3. Expected to require at least an overnight hospital admission after surgery;\n4. Age ≥18 years; and\n5. Informed consent is obtained to participate in the BRACKETS-Pilot Trial.\n\nExclusion Criteria:\n\n1. Undergoing cardiac surgery;\n2. Undergoing intracranial neurosurgery;\n3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;\n4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;\n5. Hypersensitivity or known allergy to TXA;\n6. History of seizure disorder;\n7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;\n8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;\n9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of childbearing potential and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective contraception; or\n10. Previously enrolled in the BRACKETS-Pilot Trial.\n\nEligibility criteria specific to the desmopressin factorial component of trial\n\nInclusion criteria:\n\n1\\. Included in the TXA factorial.\n\nExclusion criteria:\n\n1. The hospital does not have access to desmopressin;\n2. Planned use of prophylactic desmopressin;\n3. Most recent serum sodium concentration \\\u003C 130 mEq\u002FL;\n4. Known or suspected von Willebrand disease (any kind), hemophilia, or platelet function disorder; or\n5. Hypersensitivity or known allergy to desmopressin.",{"count":174,"type":21},100,[24],"The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.",[178,179,29,180],"Chronic Kidney Diseases","Acute Kidney Injury","Surgery",[182,121,183],"Major Noncardiac Surgery","Desmopressin",{"date":185,"type":38},"2026-05-22",{"date":187,"type":38},"2025-06-09",{"date":189,"type":21},"2027-06",{"name":191,"class":45},"Hamilton Health Sciences Corporation",3,{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":214,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":223},"100382700","phase-4-clinical-surveillance-vs-anticoagulation-for-low-risk-patients-with-isolated-subsegmental-pulmonary-embolism-100382700","NCT04263038","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial","SAFE-SSPE","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age ≥18 years\n3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE\n\nExclusion Criteria:\n\n1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or above)\n2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or palliative care during the last 6 months\n3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)\n4. Clinical instability (systolic blood pressure \\\u003C100 mm Hg or arterial Oxygen saturation \\\u003C92% at ambient air) at the time of presentation\n5. Active bleeding or at high risk of bleeding\n6. Severe renal failure (creatinine clearance \\\u003C30ml\u002Fmin)\n7. Severe liver insufficiency (Child-Pugh B or C)\n8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers\n9. Known hypersensitivity to rivaroxaban\n10. Need for therapeutic anticoagulation for another reason\n11. Therapeutic anticoagulation for \\>72 hours for any reason at the time of screening\n12. Hospitalized for \\>72 hours prior to the diagnosis of isolated SSP (hospital-acquired VTE)\n13. Known pregnancy or breast feeding (pregnancy test to be performed for women of childbearing potential)\n14. Lack of safe contraception in women of childbearing potential\n15. Refusal or inability to provide informed consent\n16. Prior enrolment in this trial",{"count":202,"type":21},276,[57],"The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents \"true\" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.",[206,207,208,209,210,211,212,213,29],"Pulmonary Embolism","Embolism","Embolism and Thrombosis","Lung Diseases","Cardiovascular Diseases","Respiratory Tract Diseases","Venous Thromboembolism","Anticoagulant-induced Bleeding",[215],"subsegmental pulmonary embolism",{"date":185,"type":38},{"date":218,"type":38},"2020-05-15",{"date":220,"type":21},"2028-05",{"name":222,"class":45},"Drahomir Aujesky",40,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":231,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100588237","how-bleeding-affects-delirium-in-older-patients-with-hip-fractures-the-improve-hip-study-100588237","NCT06938789","How Bleeding Affects Delirium in Older Patients With Hip Fractures: The IMPROVE-HIP Study","The Impact of Bleeding on Delirium Outcomes in Older Patients With Hip Fractures: A Single-Blind, Randomized Controlled Trial - The IMPROVE-HIP Study","Inclusion Criteria:\n\n* Hip fracture\n\nExclusion Criteria:\n\n* Pathological hip fracture\n* Periprosthtic fracture\n* Unable to speak or understand Danish\n* Does not wish to recieve blood transfusion\n* If the investigator finds the patient unable to cooperate to the study (e.g. in case of severe dementia and externalizing behaviour)","75 Years",{"count":233,"type":21},198,[144],"The goal of this clinical trial is to investigate whether early detection of bleeding and prompt blood transfusions can help prevent delirium in patients aged 75 and older who are admitted to the hospital with hip fractures. The main question the trial aims to answer is:\n\nDo patients aged 75 and older with hip fractures benefit from earlier treatment of anemia (low blood count) to reduce the risk of delirium?\n\nResearchers will compare early diagnosis and treatment of bleeding with standard care to determine if it helps lower the risk of developing delirium.\n\nParticipants will:\n\nUndergo blood tests, have their vital signs monitored, and be screened for delirium three times a day for the first 48 hours after surgery.\n\nReceive blood transfusions promptly if their hemoglobin levels fall below a specified threshold.\n\nAttend a follow-up visit at 30 days to assess cognitive function and overall quality of life.\n\nAttend another follow-up at 90 days to evaluate hospital readmissions and survival.",[29,237,238],"Hip Fracture","Delirium - Postoperative",[240,241,242],"Hip fracture","Delirium","Blood transfusion","2026-05-19",{"date":185,"type":38},{"date":246,"type":38},"2025-04-24",{"date":248,"type":21},"2027-06-01",{"name":250,"class":45},"University of Aarhus",2,{"id":253,"slug":254,"hasResults":12,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":192},"100633222","multi-omics-based-novel-thrombosis-and-bleeding-markers-and-risk-model-for-chd-100633222","NCT07523880","Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD","Multi-Omics-Based Development of Novel Thrombosis and Bleeding Markers and Construction of a Risk Prediction Model in Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy.\n3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment.\n4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent.\n\nFor newly enrolled patients: voluntary written informed consent provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures.\n\nExclusion Criteria:\n\nFor patients from the existing cohort:\n\n1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification.\n2. No available blood specimen, or specimen that does not meet testing requirements.\n\nFor newly enrolled patients:\n\n1. Presence of serious comorbid conditions with life expectancy ≤ 6 months.\n2. Conditions that significantly affect study compliance or the ability to complete follow-up.\n3. Contraindications to blood sampling.",{"count":260,"type":21},12154,"OBSERVATIONAL","Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.\n\nThe investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study.\n\nThe investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are better than existing ones at predicting who will develop clots or bleeding and at helping doctors decide on the best treatment for each patient.\n\nThe new aspects of this research are: (1) using advanced multi-omics technology to find novel markers specifically for Chinese patients; (2) combining clinical, biological, and imaging data to improve prediction accuracy; and (3) using machine learning to create more precise risk models.\n\nThe goal is to provide doctors with a more accurate tool to assess each patient's risk of clots and bleeding. This will help them choose the safest and most effective antiplatelet treatment, reduce serious complications, and improve patient care.",[87,29,264],"Coronary Artery Disease (CAD)",[266,267,87,29,268,269,270,271],"Coronary Heart Disease","Dual Antiplatelet Therapy","Multi-Omics","Biomarkers","Risk Prediction Model","Machine Learning","2026-04-06",{"date":274,"type":38},"2026-04-13",{"date":276,"type":38},"2025-08-01",{"date":278,"type":21},"2029-07",{"name":280,"class":45},"Xueyan Zhao",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":69},"100533720","phase-3-the-effects-of-intraoperative-tranexamic-acid-on-perioperative-bleeding-in-craniotomies-100533720","NCT06229483","The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies","Inclusion Criteria are the following:\n\n1. Adult male or female, between 18-80 years of age.\n2. Patients are scheduled to undergo a craniotomy for tumor resection.\n3. Patients\u002F Substitute Decision Maker have given written consent to participate.\n\nExclusion Criteria are the following: Patients who meet any of the following exclusion criteria will not be eligible.\n\n1. Patients with known active or previous history of thromboembolic disease or deep venous thrombosis.\n2. Patients with known pre-existing coagulopathy such as hemophilia, Von Willebrand disease, and clotting factor deficiencies.\n3. Patients with renal impairment and eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m2 as determined by the lab or calculated by using the Cockcroft Gault formula or end stage renal disease currently on dialysis.\n4. Female subjects who are pregnant or currently breastfeeding.\n5. Patients with Class 3 (high-risk) obesity BMI ≥ to 40.\n6. Patients undergoing emergency craniotomy or mini craniotomy or craniectomies.\n7. Patients who received embolization prior to surgery.","80 Years",{"count":289,"type":21},102,[24],"The goal of this clinical trial is to test the effect of a drug called tranexamic acid (TXA) on reducing blood loss in participants undergoing surgery to remove brain tumors. The main questions it aims to answer are:\n\n1. Does TXA 20 mg\u002Fkg IV bolus of TXA, and 1 mg\u002Fkg\u002Fhr infusion of TXA reduce the amount of estimated blood loss during surgery?\n2. Does TXA 20 mg\u002Fkg IV bolus of TXA, and 1 mg\u002Fkg\u002Fhr infusion of TXA prevent re-operation, disability or death related to bleeding inside the head during and after surgery? Participants are randomized to receive 20 mg\u002Fkg IV bolus of TXA or matching placebo within 30 minutes of start of surger, and then 1 mg\u002Fkg\u002Fhr infusion of TXA or matching from the start of surgery to end of surgery. Treatment allocation is blinded. Investigator will compare the two treatment arms to see whether there are differences in the amount of blood loss during surgery and bleeding-related complications. Investigators will also monitor for any side effects of TXA.",[293,29],"Brain Tumor","2026-03-18",{"date":296,"type":38},"2026-03-19",{"date":298,"type":38},"2024-04-03",{"date":300,"type":21},"2028-12-31",{"name":302,"class":45},"Stephen Lownie",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":4},"100627601","concomitant-pfa-bsaed-pvi-plus-laac-100627601","NCT07450755","Concomitant PFA Bsaed PVI Plus LAAC","Pulse Field Ablation Based Pulmonary Vein Isolation Concomitant With Left Atrial Appendage Closure - The COCONUT II Study","COCONUT_2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Willing to participate\n* Atrial fibrillation and indication for PVI (ESC guideline 2024)\n* Indication for OAC therapy (CHA2DS2VA score \\>\u002F=2)\n\nExclusion Criteria:\n\n* Contraindications for PVI and \u002F or LAA closure\n* Pregnancy\n* Previous catheter ablation for AF",{"count":312,"type":21},150,[144],"A multicenter, prospective registry of concomitant Farapulse (Boston scientific) based PVI and Watchman Flx device (Boston scientific) based LAAC procedures was planned in order to assess the acute and mid-time safety, efficacy and efficiency of this approach (COCONUT II study). If available the transseptal puncture will be performed by the VersaCross System (Boston scientific). If already available LAAC procedure will be performed utilizing the Watchman Flx pro device (Boston scientific) or the Watchman Flx device (Boston scientific).\n\nFor procedure planning, assessment of the LAA size and selection of the Watchman Flx device a preprocedural cardiac computed tomography in combination with the TruePLan Software is recommended.",[316,29,28],"Atrial Fibrillation (AF)",[318,319,320],"Catheter ablation","Pulsed field ablation","LAAClosure","2026-03-11",{"date":323,"type":38},"2026-03-12",{"date":325,"type":21},"2026-03-01",{"date":327,"type":21},"2027-12-31",{"name":329,"class":330},"Asklepios proresearch","INDUSTRY",{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":287,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":4},"100629166","phase-3-switch-apixaban-vs-vitamin-k-in-hm3-100629166","NCT07471139","SWITCH: Apixaban vs Vitamin K in HM3","The SWITCH Trial: A Randomized Controlled Study of Apixaban Versus Vitamin K Antagonists in Patients With HeartMate 3 Left Ventricular Assist Devices","Inclusion Criteria:\n\n* Participants will have HeartMate3 LVAD implanted \\> 3 months before enrollment\n* ≥ 18 years old\n* Treated with WARFARIN SODIUM\n* Participant must provide written informed consent prior to any clinical investigation related procedure\n* In female participants of childbearing capability, not currently pregnant and on appropriate contraception\n\nExclusion Criteria:\n\n* Participation in any other clinical investigation(s) involving a Mechanical Circulatory Support (MCS) device, or interventional investigation(s) likely to confound study results or affect study outcome\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results\n* Known allergy to Apixaban\n* Bridge to transplant\n* Severe renal dysfunction Estimated Glomerular Filtration Rate (eGFR) \\\u003C20\n* History of major bleeding event with subsequent reduction of INR goal to \\\u003C 1.8\n* Apixaban dose reduction criteria (Age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg\u002FdL)\n* Aortic root thrombus",{"count":339,"type":21},460,[24],"This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.",[83,343,29,344,28,345],"Heart Failure","Thrombosis; Artery","Heart Transplant",{"date":347,"type":38},"2026-03-13",{"date":349,"type":21},"2026-06",{"date":351,"type":21},"2029-06",{"name":353,"class":45},"Columbia University",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":69},"100595464","phase-2-factor-viii-inhibitor-bypass-activity-feiba-versus-fresh-frozen-plasma-as-first-line-therapy-for-bleeding-after-cardiac-surgery-100595464","NCT07032792","Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, aged 18 years or above\n* Undergoing nonemergent non-coronary cardiac surgery with the use of cardiopulmonary bypass\n* Patient with microvascular bleeding requiring factor transfusion as deemed by the patient care team\n\nExclusion Criteria:\n\n* Contraindication to the administration of FEIBA or known anaphylactic or severe hypersensitivity reaction to FEIBA or any of its components\n* Disseminated intravascular coagulation\n* Acute thrombosis or embolism, including myocardial infarction\n* Pregnancy\n* Patients that are not able or do not want to consent for themselves\n* Patients with known coagulation disorders\n* Patients who received coronary artery bypass surgery\n* Patients who received transplants or ventricular assist devices\n* Patients on extracorporeal membrane oxygenator support\n* Patients with heparin induced thrombocytopenia\n* Patients who do not wish to receive blood products even when it is deemed medically necessary",{"count":361,"type":21},140,[116],"Coagulopathic-induced bleeding after cardiopulmonary bypass in cardiac surgery patients is common and is associated with adverse outcomes in cardiac surgery. The hypothesis of the study is that FEIBA will be a more effective treatment than standard of care (FFP) in cardiac surgery patients who have coagulopathic-induced bleeding. This study is being conducted to determine the efficacy of FEIBA versus FFP as first line therapy in correcting coagulopathic induced microvascular bleeding in cardiac surgery patients.",[365,180,29],"Cardiac Disease","2026-03-09",{"date":321,"type":38},{"date":369,"type":38},"2025-11-03",{"date":371,"type":21},"2029-11",{"name":373,"class":45},"Northwell Health",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":192},"100566453","phase-4-aspirin-and-hemocompatibility-events-in-chronic-advanced-heart-failure-patients-with-assist-device-100566453","NCT06655376","Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device","Delayed ARIES: Aspirin and Hemocompatibility Events in Advanced Heart Failure Patients Chronically Supported With a Left Ventricular Assist Device","Inclusion Criteria:\n\n* Participant will have HeartMate3 LVAD implanted \\> 3 months before enrollment.\n* \\>18 years old\n* Treated with aspirin and VKA\n* Participant must provide written informed consent prior to any clinical investigation-related procedure\n\nExclusion Criteria:\n\n* Investigator-mandated antiplatelet therapy for other conditions (including mandated presence or absence of antiplatelet agent)\n* Participation in any other clinical investigation(s) involving an MCS device, or interventional investigation(s) likely to confound study results or affect study outcome\n* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results\n* Pregnant and on appropriate contraception",{"count":382,"type":21},128,[57],"Heart failure is a world epidemic. LVADs are increasingly used as they have demonstrated improved survival rates compared to optimal medical management. Improving outcomes have been seen with the newer LVAD technology, the HeartMate 3 (Abbott, Chicago, IL), however, hemocompatibility related adverse events, including thrombosis and bleeding, are still a major cause of morbidity and mortality. The recent ARIES trial showed that in patients with advanced heart failure treated with a HeartMate3 LVAD, avoidance of aspirin as part of an antithrombotic regimen, which includes vitamin K antagonist (VKA), is not inferior to a regimen containing aspirin, does not increase thromboembolism risk, and is associated with a reduction in bleeding events.\n\nThis clinical investigation is a prospective, randomized, controlled study of advanced heart failure patients supports with the HeartMate3 for more then 3 months with two different antithrombotic regimens: VKA with and without aspirin. The objective of this investigation is to study the safety and efficacy of an antithrombotic regimen without antiplatelet therapy.",[29,386],"Clot Blood","2026-02-24",{"date":389,"type":38},"2026-02-27",{"date":391,"type":38},"2024-10-02",{"date":393,"type":21},"2027-04-01",{"name":353,"class":45},{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":405,"briefSummary":406,"conditions":407,"keywords":411,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100621599","safety-of-perioperative-anticoagulation-management-in-people-with-active-cancer-undergoing-cancer-related-surgery-or-procedures-ace-high-study-100621599","NCT07372716","Safety of Perioperative Anticoagulation Management in People With Active Cancer Undergoing Cancer-Related Surgery or Procedures (ACE-HIGH Study)","Active Cancer Patients Having Cancer Related Invasive Procedures or Surgery and Needing Perioperative Management of Anticoagulation Therapy (ACE-HIGH): A Prospective Management Cohort Study","ACE-HIGH","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Prescribed a Direct Oral Anticoagulant (DOAC), warfarin (International Normalized Ratio (INR) target 2.0-3.0) or Low Molecular Weight Heparin (LMWH) (75-100% weight-based therapeutic dosing) for stroke prevention in Atrial Fibrillation (AF) or the treatment of Venous Thromboembolism (VTE). Eligible DOAC regimens include full-dose (therapeutic) DOAC regimens appropriate for age and renal function. Eligible DOAC regimens include:\n\n  i. Apixaban 10 mg po BID (VTE) ii. Apixaban 5 mg po BID (AF or VTE) iii. Apixaban 2.5 mg po BID (AF) iv. Rivaroxaban 15 mg po BID (VTE) v. Rivaroxaban 20 mg po OD (AF or VTE) vi. Rivaroxaban 15 mg po OD (AF only) vii. Edoxaban 60 mg po OD (AF or VTE) viii. Edoxaban 30 mg po OD (AF or VTE) ix. Dabigatran 150 mg po BID (AF or VTE) x. Dabigatran 110 mg po BID (AF)\n* Has active cancer, defined as:\n\n  i. cancer diagnosed within 6 months ii. recurrent, regionally advanced, or metastatic cancer iii. cancer for which treatment had been administered within 6 months before enrolment iv. hematologic cancer that is not in remission v. Patients who are felt to likely have active cancer based on clinical\u002Fimaging characteristics but are awaiting tissue confirmation and are scheduled for a biopsy procedure are eligible for trial inclusion\n* Is undergoing a planned cancer-related inpatient or outpatient invasive procedure or cancer surgery (to diagnose, treat or palliate cancer; at investigator's discretion)\n* Interruption of anticoagulation therapy for the planned procedure is required.\n\nExclusion Criteria:\n\n* Presence of any mechanical prosthetic heart valve\n* Known pregnancy or breastfeeding\n* Severe renal insufficiency (Creatinine Clearance (CrCl) \\\u003C 30 mL\u002Fmin or \\\u003C 25 mL\u002Fmin for Apixaban users)\n* Condition that might impair adherence to the study protocol (e.g., cognitive impairment, geographic inaccessibility) as determined by the treating physician\n* Allergy to heparin or a history of (Heparin Induced Thrombocytopenia (HIT)\n* More than one surgery\u002Fprocedure planned during the study period\n* Previous study participation\n* Inability to provide informed consent",{"count":404,"type":21},700,[144],"The purpose of this study is to help find how safe current practices are when managing blood thinners in people with cancer who are having surgery or medical procedures. Investigators will also measure how often bleeding or clotting problems happen in this setting. The goal is to use this information to improve future care and reduce these risks for patients. This study will determine whether contemporary practices can be safely applied to cancer patients, and also evaluate the blood thinner level left over in patient's body at the time of surgery.",[87,408,409,316,410,29],"Cancer","Thrombosis, Deep Vein","Venous Thromboembolic Event",[412,413,408,414,415,416],"thrombosis","Atrial fibrillation","Anticoagulant Interruption","VTE","bleeding","2026-02-05",{"date":419,"type":38},"2026-02-06",{"date":421,"type":21},"2026-03",{"date":423,"type":21},"2031-12",{"name":425,"class":45},"Ottawa Hospital Research Institute",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":433,"targetDuration":435,"studyType":261,"phases":4,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":69},"100620011","incidence-of-bleeding-thrombosis-and-transfusion-requirements-in-icu-patients-with-covid-19-supported-with-veno-venous-extracorporeal-membrane-oxygenation-100620011","NCT07352072","Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation","Incidence of Bleeding, Thrombosis and Transfusion Requirements in ICU Patients With COVID-19 Supported With Veno-venous Extracorporeal Membrane Oxygenation: a Single-center Retrospective Cohort Study","Inclusion criteria:\n\n* Adults\n* Polymerase chain reaction (PCR) verified COVID-19 infection\n* Supported with V-V ECMO in this center\n\nExclusion criteria:\n\n\\- none",{"count":434,"type":21},50,"90 Days","The investigators aim to assess the risk of bleeding and thrombo-embolic complications as well as benefit and harm of blood product transfusion and anticoagulation therapy in adult ICU patients with COVID-19 supported with V-V ECMO",[438,29,87,439,440],"VV ECMO","Transfusion Adverse Reaction","COVID-19","2026-01-27",{"date":443,"type":38},"2026-01-29",{"date":445,"type":21},"2026-01",{"date":447,"type":21},"2026-12",{"name":449,"class":45},"Rigshospitalet, Denmark",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":457,"enrollmentInfo":458,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100621129","bleeding-management-n-open-heart-surgery-100621129","NCT07366606","Bleeding Management İn Open Heart Surgery","Development of a Thromboelastography-Based Algorithm for Targeted Bleeding Management in Open Heart Surgery: An In Vitro Clinical Study","Inclusion Criteria:\n\n* Patients who will undergo open heart surgery\n* Patients who have given informed consent\n\nExclusion Criteria:\n\n* Patients undergoing emergency surgery\n* Patients with known congenital coagulation disorders\n* Patients with a known history of bleeding diathesis\n* Patients receiving uninterrupted anticoagulant therapy at an optimal time\n* Patients with renal failure under dialysis treatment\n* Patients with active malignancy\n* Patients who did not provide informed consent","84 Years",{"count":361,"type":21},[144],"This study aims to develop an algorithm that can guide targeted bleeding management through thromboelastography (TEG) viscoelastic testing performed on blood samples from patients undergoing open heart surgery. The goal is to develop an algorithm that supports targeted bleeding management based on TEG parameters. The study is prospective, in vitro, and non-invasive. The material will consist of residual blood samples from open heart surgery patients. Analyses will be performed using TEG parameters (R time, K time, MA, LY30). Patients will be randomized using a closed-envelope method and divided into two groups: anesthesiologist standard clinical observation-control (Group K) and anesthesiologist standard clinical observation and TEG analysis (Group T). The sample size is 70 patients per group. From an ethical standpoint, this study uses anonymous data without additional blood collection and ensures patient safety.",[462,463,29],"Thromboelastography (TEG)","Open Heart Surgery","2026-01-16",{"date":466,"type":38},"2026-01-26",{"date":468,"type":21},"2026-04",{"date":470,"type":21},"2027-12",{"name":472,"class":45},"Serkan Uckun",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":287,"enrollmentInfo":481,"targetDuration":4,"studyType":22,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":4},"100620220","the-feasibility-safety-and-efficacy-of-eus-guided-pse-a-cohort-study-100620220","NCT07354789","The Feasibility, Safety, and Efficacy of EUS-Guided PSE: A Cohort Study","The Feasibility, Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Partial Splenic Embolization(PSE): A Cohort Study","EUS; PSE","Inclusion Criteria:\n\n1. Aged 18-80 years.\n2. Diagnosis of liver cirrhosis based on clinical, laboratory, and imaging examinations.\n3. Complicated with gastrointestinal bleeding caused by esophagogastric varices.\n4. Patients with hypersplenism and thrombocytopenia (platelet count \\\u003C 100 × 10\\^9\u002FL).\n\nExclusion Criteria:\n\n1. Patients who have previously undergone splenectomy, PSE, transjugular intrahepatic portosystemic shunt (TIPS), varicocelectomy, sclerotherapy, or balloon-occluded retrograde transvenous obliteration.\n2. Hepatocellular carcinoma or other malignant tumors.\n3. Patients with hepatic encephalopathy who are unable to cooperate, or those with liver failure or a Child-Pugh score \\>13.\n4. Patients with allergies to intravenous anesthetics.\n5. Patients with unstable vital signs, associated organ dysfunction, active infection, or cardiopulmonary insufficiency, who cannot tolerate endoscopy.\n6. Patients who are unable or unwilling to provide informed consent.\n7. Uncorrectable coagulation disorders (INR \\>1.5 and\u002For fibrinogen \\\u003C120 mg\u002FdL) or uncorrectable thrombocytopenia (platelet count \\\u003C20 × 10\\^9\u002FL).\n8. Patients who have used beta-blockers within the past 24 hours",{"count":434,"type":21},[144],"Bleeding from esophagogastric varices in patients with liver cirrhosis is often life-threatening. Thrombocytopenia caused by hypersplenism secondary to portal hypertension is an independent risk factor for such gastrointestinal bleeding. Studies have confirmed that partial splenic embolization (PSE) can effectively reduce portal pressure and decrease the risk of rebleeding.\n\nTraditional treatments mainly include total splenectomy and X-ray-guided transarterial partial splenic embolization (X-PSE). Although total splenectomy can completely remove the lesion, its application is limited by issues such as increased risks of postoperative infection, thrombosis, and long-term immune dysfunction. Currently, X-PSE has become the mainstream treatment. This technique involves superselective catheterization of the splenic artery branches using a microcatheter and injecting embolic microspheres to achieve partial splenic embolization, thereby preserving partial splenic function. However, X-PSE relies on radiological intervention techniques and carries risks such as radiation exposure, contrast-induced nephropathy, and non-target embolization (e.g., pancreatic necrosis). Additionally, its ability to locate small arterial branches in the splenic hilum is limited.\n\nEndoscopic ultrasound (EUS) integrates an ultrasound probe at the tip of an endoscope, enabling high-resolution imaging and fine-needle aspiration therapy of the pancreas, gastrointestinal tract, posterior mediastinum, and retroperitoneal structures. With color Doppler functionality, EUS can clearly identify abdominal vessels and their blood flow signals. Since the spleen and splenic vessels are located posterior to the gastric fundus, EUS can clearly visualize the vascular structures of the splenic hilum via a transgastric approach.\n\nCompared to X-PSE, EUS-guided PSE offers the following advantages: a shorter puncture path; avoidance of iodinated contrast agents, making it suitable for patients with iodine allergies or renal insufficiency; no X-ray exposure for patients or operators; the ability to combine treatment for esophagogastric varices in the same procedure, thereby simplifying the process, reducing costs, and shortening hospital stays; and, since there is no arterial puncture site on the body surface, patients do not require prolonged limb immobilization postoperatively, resulting in an overall better healthcare experience.\n\nCurrent literature and small-sample retrospective studies have reported on this technique, but the included cases are mostly limited to patients with mild liver function impairment, and there is a lack of systematic evaluation of its effect on portal pressure reduction.\n\nThe investigators' center integrates the advantages of EUS and X-PSE to perform EUS-guided transgastric puncture for precise injection of embolic materials into the splenic artery branches in patients with liver cirrhosis, gastrointestinal bleeding, and hypersplenism, achieving partial splenic embolization. This study aims to evaluate the safety and efficacy of EUS-guided PSE. The primary endpoint is safety, including the incidence of complications such as intraoperative bleeding, postoperative fever, and abdominal pain scores. Secondary endpoints include efficacy indicators: platelet count, portal pressure gradient, embolization area on CT, incidence of gastrointestinal rebleeding, as well as hospitalization costs and length of stay.",[485,486,29],"Cirrhosis","Portal Hypertension","2026-01-12",{"date":489,"type":38},"2026-01-21",{"date":491,"type":21},"2026-01-20",{"date":493,"type":21},"2027-03-15",{"name":495,"class":45},"Qilu Hospital of Shandong University",{"id":497,"slug":4,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":504,"briefSummary":505,"conditions":506,"keywords":510,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":521,"locationsCount":251},"100527420","NCT06147531","Delayed Cold-Stored Platelets -PLTS-1","A Clinical Comparison of Cold-stored and Room Temperature-stored Allogeneic Platelet Transfusions in Bleeding Adult Cardiac Surgery Patients - A Randomized Multicentre Pilot Study (PLTS-1 Study)","PLTS-1","Inclusion Criteria:\n\nAdult (≥18 years old) patients undergoing elective cardiac surgery with CPB will be eligible for inclusion if they are planned to undergo at least moderately complex surgery or have a preoperative platelet count ≤150,000 x106\u002FL (this is a group at high risk of requiring platelet transfusions post-CPB).\n\nModerately complex index surgery is defined as:\n\n1. repair\u002Freplacement of more than one valve;\n2. aorta (root\u002Fascending\u002Farch) replacement;\n3. any combination of coronary artery bypass grafting, valve repair\u002Freplacement, or aorta (root\u002Fascending\u002Farch) replacement; or\n4. re-do procedures consisting of a repair or revision of a prior cardiac intervention.\n\nExclusion Criteria:\n\nPatients will be excluded if cold-stored platelets are not going to be available at the time of surgery or if the patient:\n\n1. has a congenital or acquired hemostatic disorder (including platelet refractoriness due to anti-platelet and anti-human leukocyte antigen \\[HLA\\] antibodies) and\u002For requires specially matched platelets (including patients with anaphylaxis to blood due to Immunoglobulin A \\[IgA\\] deficiency),\n2. has known contraindications to heparin, thereby excluding cases where non-reversible anticoagulants (i.e. argatroban) are used,\n3. is on warfarin or direct oral anticoagulants (dabigatran, rivaroxaban, apixaban or edoxaban) within 3 days prior to surgery,\n4. is on antiplatelet drugs within 5 days prior to surgery (excluding acetylsalicylic acid \\[ASA\\]),\n5. refuses allogeneic blood products,\n6. has a known pregnancy,\n7. has already enrolled in this study,\n8. is enrolled in another interventional clinical trial where routine care and management are altered,\n9. has hemodynamic instability defined as critical care admission, vasopressor, or inotrope dependence prior to index surgery, or\n10. has pre-operative requirement for, or expected post-operative dependence upon mechanical circulatory support (i.e., intra-aortic balloon pump, ventricular assist device).",{"count":312,"type":21},[116],"PLTS-1 is a multicentre, randomized, controlled, pilot trial, using a conventional, parallel group, two-armed design at 2 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT to determine the non-inferiority of cold-stored platelets compared to conventional platelets with respect to hemostatic effectiveness (total number of allogeneic blood products transfused within 24 hours after CPB), as well as safety.",[507,29,508,509],"Platelets","Cardiopulmonary Bypass","Cardiac Surgery",[511,512,513,514],"Blood Platelets","Cardiac surgical procedure","Blood Preservation\u002FMethods","Blood Preservation\u002FAdverse Effects","2025-12-22",{"date":517,"type":38},"2025-12-29",{"date":519,"type":38},"2024-06-05",{"date":447,"type":21},{"name":522,"class":45},"University Health Network, Toronto",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":533,"conditions":534,"keywords":543,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":561},"100616764","hip-fracture-surgery-timing-and-blood-transfusion-risk-in-patients-on-doacs-100616764","NCT07309848","Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs","Blood Transfusion Risk After Early vs. Delayed Surgery in Hip Fracture Patients on Direct Oral Anticoagulants: A Natural Experiment","OPTIMIZEDOAC","Inclusion Criteria:\n\n* Isolated hip fracture classified as AO\u002FOTA 31A or 31B requiring surgical intervention.\n* Current DOAC use with the last dose taken ≤24 hours before emergency department (ED) presentation\n\nExclusion Criteria:\n\n* Pathologic or periprosthetic hip fractures.\n* Fracture sustained \\>24 hours before ED presentation.\n* Inter-hospital transfer.\n* Hematologic disorders (e.g., thalassemia, sickle cell disease, aplastic anemia, myelodysplastic syndromes, leukemia).\n* Use of a non-EMA-approved DOAC (e.g., betrixaban).",{"count":532,"type":21},374,"This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting longer can also increase risks such as complications and longer hospital stays. The purpose of this study is to find out whether operating within 24 hours is as safe as delaying surgery beyond 24 hours. Specifically, the investigators want to know if early surgery does not lead to a higher need for blood transfusions compared to delayed surgery.",[535,536,537,538,539,29,540,541,542],"Blood Transfusion","Hip Fracture Surgeries","Geriatric","Bleeding Complications","Bleeding as Surgical Complication (Treatment)","Blood Transfusions","Blood Transfusion Complication","Direct Oral Anticoagulants (DOACs)",[544,545,546,547,548,549,416,550,551,552],"natural experiment","doac","direct oral anticoagulant","hip fracture","geriatric","surgery","blood transfusion","early","delayed","2025-12-15",{"date":555,"type":38},"2025-12-30",{"date":557,"type":38},"2025-11-01",{"date":327,"type":21},{"name":560,"class":45},"St. Antonius Hospital",7,{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":570,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":572,"conditions":573,"keywords":577,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":69},"100599368","impact-of-iv-iron-on-bleeding-symptoms-in-iron-deficient-patients-with-inherited-bleeding-disorders-100599368","NCT07083583","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders: a Single-arm Prospective Observational Study","IRON-BD","Inclusion Criteria:\n\n1. Males and Females \\> 15 years of age\n2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause)\n3. Evidence of Iron Deficiency (Ferritin \\\u003C 50 ng\u002FmL)\n4. Receiving IV iron at Hemophilia Center of Western Pennsylvania\n5. Willingness to have blood drawn\n6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.\n\nExclusion Criteria:\n\n1. Previous thrombosis, VTE History.\n2. Platelet count \\\u003C 100,000 \\* 109\u002FL\n3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.","15 Years",{"count":223,"type":21},"This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \\\u003C50ng\u002FdL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes",[574,575,576,29],"Bleeding Disorders","Iron","Platelet",[578,579,580],"Iron deficiency","bleeding disorder","platelet function","2025-10-01",{"date":583,"type":38},"2025-10-03",{"date":585,"type":38},"2025-08-08",{"date":131,"type":21},{"name":588,"class":45},"Nicoletta C Machin",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":123,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":596,"enrollmentInfo":597,"targetDuration":4,"studyType":22,"phases":598,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":69},"100607752","intravenous-tranexamic-acid-100607752","NCT07192640","Intravenous Tranexamic Acid","PERIOPERATIVE USE OF INTRAVENOUS TRANEXAMIC ACID FOR HIGH BMI PATIENTS GOING THROUGH BARIATRIC SURGERIES","Inclusion Criteria:\n\n* High-risk patients, with obesity, BMI more than 45,\n* Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.\n\nExclusion Criteria:\n\n* patients with active thromboembolic disorders.\n* Patients with preexisting renal dysfunction,","60 Years",{"count":382,"type":21},[144],"Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.",[601,602,29],"Obese Patients","Obese Patients With Bariatric Surgery","2025-09-23",{"date":605,"type":38},"2025-09-25",{"date":607,"type":21},"2025-10-15",{"date":609,"type":21},"2026-03-30",{"name":611,"class":45},"Ain Shams University",{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":22,"phases":621,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":4},"100593932","phase-4-life-saving-treatment-with-dry-plasma-for-massive-bleeding-in-an-pre-hospital-setting-100593932","NCT07012863","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting - - a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age.\n* Patients who lack clinical signs of major bleeding.",{"count":620,"type":21},650,[57],"The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock.\n\nResearchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.",[29,624,625,626,627,628],"Aortic Rupture","Gastrointestinal Hemorrhage","Obstetric Bleeding","Blunt Injury","Penetrating Injury","2025-09-16",{"date":631,"type":38},"2025-09-17",{"date":633,"type":21},"2026-01-01",{"date":635,"type":21},"2027-09-30",{"name":637,"class":105},"Vastra Gotaland Region",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":17,"minAge":645,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":648,"conditions":649,"keywords":652,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":659,"leadSponsor":661,"locationsCount":4},"100605151","role-of-frailty-in-bleeding-risk-prediction-in-acute-coronary-syndrome-100605151","NCT07158788","Role of Frailty in Bleeding Risk Prediction in Acute Coronary Syndrome","Incremental Value of Frailty Indices in Bleeding Risk Prediction Among Patients With Acute Coronary Syndrome","Inclusion Criteria:\n\n1. \\- Patients must be suffering from acute coronary syndrome ( STEMI - NSTEMI ) at the time of recruitment\n2. \\- Patients must be older than 65 years\n\nExclusion Criteria:\n\n1. \\- Patients younger than 65 years\n2. \\- Refusal of participation\n3. \\- In - hospital death unrelated to bleeding","65 Years",{"count":647,"type":21},850,"Studying the incremental role of frailty in predicting in-hospital, short-term (30 days), and mid-term (6 months) bleeding in ACS patients.",[650,651,29],"Frailty","Acute Coronary Syndrome",[650,653,416,654],"acute coronary syndrome","bleeding risk prediction","2025-09-04",{"date":657,"type":38},"2025-09-08",{"date":581,"type":21},{"date":660,"type":21},"2027-09-01",{"name":662,"class":45},"Assiut University",{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":4,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":670,"enrollmentInfo":671,"targetDuration":4,"studyType":261,"phases":4,"briefSummary":673,"conditions":674,"keywords":676,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":682,"lastUpdatePostDateStruct":683,"startDateStruct":685,"completionDateStruct":687,"leadSponsor":689,"locationsCount":69},"100602063","clinical-study-on-emergency-treatment-of-cerebral-arteriovenous-malformation-bleeding-100602063","NCT07118631","Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding","Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding and Continuous Improvement of Medical Quality Based on Neurosurgery Hybrid Surgery Platform","Inclusion Criteria:\n\n* Head CT confirmed cerebral hemorrhage, with indications for emergency surgery\n* Head CTA suggested that the responsible lesion may be cerebral arteriovenous malformation\n* Spetzler-Martin classification 1 to 4; Cerebral arteriovenous malformation Spetzler-Martin classification is as follows: ① Nidus size: small (\\\u003C3 cm) is scored as 1 point, medium (3 cm\\~6 cm) is scored as 2 points, and large (≥6 cm) is scored as 3 points; ② Adjacent brain functional areas: 0 points for non-functional areas, 1 point for functional areas; ③ Drainage veins: 0 points for superficial veins, 1 point for deep veins);\n* Aged 18 to 70 years old, with systemic conditions that can tolerate surgery;\n* Agree to surgical treatment and sign an informed consent form.\n\nExclusion Criteria:\n\n* Consciousness disorder due to serious underlying diseases\n* Patients or family members who refuse surgery\n* Perinatal and pregnancy patients","70 Years",{"count":672,"type":21},162,"Cerebral arteriovenous malformation (AVM) is the leading cause of brain hemorrhage in young adults, characterized by sudden onset and rapid progression. The hybrid neurosurgical operating room is a diagnostic and therapeutic platform that integrates neurointervention and microneurosurgery, offering advantages such as one-stop rapid treatment and multimodal therapeutic approaches.\n\nThis study aims to focus on patients with acute cerebral AVM-related hemorrhage through a multicenter, prospective, registry-based research approach. In the hybrid neurosurgical operating room, emergency cerebral angiography, neurointerventional embolization, microsurgical resection of the vascular malformation, or minimally invasive hematoma evacuation will be performed to explore the indications and advantages of the hybrid neurosurgical operating platform in emergency AVM hemorrhage management. The study seeks to establish standardized diagnostic and treatment protocols and operational workflows for emergency AVM hemorrhage management in the hybrid operating room. Through continuous quality improvement, the study aims to further reduce patient morbidity and mortality.\n\nThis research will not only enhance the diagnostic and therapeutic level of cerebral AVM-related hemorrhage and improve patient outcomes but also effectively reduce medical costs and societal burdens.",[675,29],"Arteriovenous Malformation",[677,678,679,680,681],"Cerebral hemorrhage","cerebral arteriovenous malformation","hybrid surgery","functional prognosis","quality improvement system","2025-08-11",{"date":684,"type":38},"2025-08-12",{"date":686,"type":38},"2025-04-01",{"date":688,"type":21},"2028-01-31",{"name":690,"class":45},"Beijing Tiantan Hospital"]